Karakurt Ilbey, Aydoğdu Ayça, Çıkrıkcı Sevil, Orozco Jesse, Lin Liwei
Department of Mechanical Engineering, University of California Berkeley, Berkeley, CA 94720, USA.
Department of Mechanical Engineering, University of California Berkeley, Berkeley, CA 94720, USA; Department of Chemical Engineering and Biomolecular Engineering, University of California Berkeley, Berkeley, CA 94720, USA; Department of Food Technology, Canakkale 18 Mart University, Canakkale 17020, Turkey.
Int J Pharm. 2020 Jun 30;584:119428. doi: 10.1016/j.ijpharm.2020.119428. Epub 2020 May 20.
Patients' genetic characteristics, age, gender, diet, and lifestyle affect the success of medical treatment. The treatment's effectiveness can be increased by using personalized medication; however, using conventional large-scale drug production methods can restrict tablet geometry and drug dosage combinations. To create these personalized drugs, 3D printing has been studied as an alternative production method. In this study, stereolithography 3D printing is used to create custom tablet geometries using a novel biocompatible photochemistry consisting of ascorbic acid (AA) encapsulated in a poly(ethylene glycol) dimethacrylate (PEGDMA)-based polymer network and polymerized using riboflavin as a photoinitiator. The printing process is customized for the chemistry and different geometries (small and large tablet, coaxial annulus, 4-circle pattern and honeycomb pattern) with surface area to volume ratios ranging from 0.6 to 1.83 are fabricated. The tablets' microstructures are examined and the cumulative release rates in gastrointestinal conditions are analyzed periodically for 6 h. After 1 h of release, honeycomb and coaxial annulus tablet gels exhibit higher release rates at approximately 80%. The experimental data is fitted to empirical release kinetic models and the Higuchi model is shown to yield the best fitting results. Overall, by using a novel biocompatible photochemistry and 3D printing we have shown that it is possible to successfully load and release ascorbic acid as a model agent, opening up a new class of manufacturing protocols to encapsulate ascorbic acid and other water-soluble vitamins as well as many different drugs for drug delivery applications.
患者的遗传特征、年龄、性别、饮食和生活方式会影响治疗效果。使用个性化药物可提高治疗效果；然而，采用传统大规模药物生产方法会限制片剂的几何形状和药物剂量组合。为了制造这些个性化药物，人们研究了3D打印作为一种替代生产方法。在本研究中，采用立体光刻3D打印技术，利用一种新型生物相容性光化学方法制造定制的片剂几何形状，该方法由包裹在聚（乙二醇）二甲基丙烯酸酯（PEGDMA）基聚合物网络中的抗坏血酸（AA）组成，并使用核黄素作为光引发剂进行聚合。针对该化学方法和不同几何形状（小片剂和大片剂、同轴环、4圆图案和蜂窝图案）定制打印工艺，制造出表面积与体积比在0.6至1.83之间的片剂。对片剂的微观结构进行检查，并定期分析其在胃肠道条件下6小时内的累积释放率。释放1小时后，蜂窝状和同轴环片剂凝胶的释放率较高，约为80%。将实验数据拟合到经验释放动力学模型，结果表明Higuchi模型拟合效果最佳。总体而言，通过使用新型生物相容性光化学和3D打印技术，我们已证明能够成功地载入和释放作为模型药物的抗坏血酸，开辟了一类新的制造方案，用于封装抗坏血酸和其他水溶性维生素以及许多不同的药物用于药物递送应用。
